REVIVE trial: Retrograde delivery of autologous bone marrow in patients with heart failure

Stem Cells Translational Medicine

Volumn 4, Issue 9, 2015, Pages 1021-1027

  Patel, Amit N ^a   Mittal, Sanjay ^b   Turan, Goekmen ^c   Winters, Amalia A ^a   Henry, Timothy D ^d   Ince, Hueseyin ^e   Trehan, Naresh ^b  

^a UNIVERSITY OF UTAH   (United States)

^b Medanta Medicity   (India)

^c ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

Author keywords

Cell transplantation; Coronary sinus; Heart failure; Retrograde approach

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; TROPONIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; END SYSTOLIC DIAMETER; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HEMATOMA; HUMAN; LEFT VENTRICULAR END SYSTOLIC DIAMETER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; AGED; AUTOTRANSPLANTATION; BIOLOGICAL THERAPY; BONE MARROW; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CORONARY SINUS; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY;

ADULT; AGED; BIOMARKERS; BONE MARROW; BONE MARROW TRANSPLANTATION; CELL- AND TISSUE-BASED THERAPY; CORONARY SINUS; FEMALE; HEART FAILURE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; STROKE VOLUME; TRANSPLANTATION, AUTOLOGOUS; VENTRICULAR FUNCTION, LEFT;

EID: 84940099408     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2015-0070     Document Type: Article

References (29)

1. World Health Organization. Report of the global survey on the progress in national chronic diseases prevention and control. 2007. Available at: http://www. who. int/chp/ncd_capacity/CCS_2005. pdf?ua=1. Accessed April 1, 2015.
2. Go AS, Mozaffarian D, Roger VL et al. Executivesummary: Heart disease andstrokestatistics-2013 Update: A report from the American HeartAssociation. Circulation 2013; 127: 143-152.
3. Ford ES, Ajani UA, Croft JB et al. Explaining thedecrease inU. S. deaths fromcoronary disease, 1980-2000. N Engl J Med 2007; 356: 2388-2398.
4. U. S. Department of Commerce Economics and Statistics Administration U. S. Census Bureau. Age projections. http://www. censusscope. org/us/chart_age. htm. Accessed April 1, 2015.
5. National Center for Health Care Statistics. http://www. cdc. gov/nchs. Accessed April 1, 2015.
6. Miller LW, Guglin M. Patient selection for ventricular assist devices: A moving target. JAm Coll Cardiol 2013; 61: 1209-1221.
7. Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHAguideline for themanagementof heart failure: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: 1810-1852.
8. Sanganalmath SK, Bolli R. Cell therapy for heart failure: Acomprehensiveoverviewof experimental and clinical studies, current challenges, and futuredirections. Circ Res 2013; 113: 810-834.
9. Matsa E, Sallam K, WuJC. Cardiac stem cell biology: Glimpse of the past, present, and future. Circ Res 2014; 114: 21-27.
10. Hajjar RJ. Potential of gene therapy as a treatment for heart failure. J Clin Invest 2013; 123: 53-61.
11. Jeevanantham V, Butler M, Saad A et al. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: A systematic review and meta-analysis. Circulation 2012; 126: 551-568.
12. Meliga E, Strem BM, Duckers HJ et al. Adipose-derived cells. Cell Transplant 2007; 16: 963-970.
13. Murry CE, Pu WT. Reprogramming fibroblasts into cardiomyocytes. N Engl J Med 2011; 364: 177-178.
14. Song K, Nam YJ, Luo X et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 2012; 485: 599-604.
15. Leri A, Kajstura J, Anversa P. Role of cardiac stem cells in cardiac pathophysiology: A paradigm shift in human myocardial biology. Circ Res 2011; 109: 941-961.
16. Patel AN, Vargas V, Revello P et al. Mesenchymal stem cell population isolated from the subepithelial layer of umbilical cord tissue. Cell Transplant 2013; 22: 513-519.
17. Bockeria L, Bogin V, Bockeria O et al. Endometrial regenerative cells for treatment of heart failure: A new stem cell enters the clinic. J Transl Med 2013; 11: 56.
18. Menasché P, Hagège AA, ScorsinMet al. Myoblast transplantation for heart failure. Lancet 2001; 357: 279-280.
19. Dib N, Menasche P, Bartunek JJ et al. Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: A report of the International Society for Cardiovascular Translational Research. JACC Cardiovasc Interv 2010; 3: 265-275.
20. Perin EC, Silva GV. Stem cell therapy in end-stage ischaemic heart failure: A catheterbased therapeutic strategy targeting myocardial viability. Eur Heart J Suppl 2006; 8(suppl H): H46-H51.
21. Talwalkar NG, Lawrie GM, Earle N et al. Can retrograde cardioplegia alone provide adequate protection for cardiac valve surgery? Chest 1999; 115: 135-139.
22. Tuma J, Fernández-Vi~na R, Carrasco A et al. Safety and feasibility of percutaneous retrograde coronary sinus delivery of autologous bone marrow mononuclear cell transplantation in patients with chronic refractory angina. J Transl Med 2011; 9: 183.
23. Zakharova L, Nural-Guvener H, Feehery L et al. Retrograde coronary vein infusion of cardiac explant-derived c-Kit+ cells improves function in ischemic heart failure. J Heart Lung Transplant 2014; 33: 644-653.
24. Patel AN, Silva F, Winters AA. Stem cell therapy for heart failure. Heart Fail Clin 2015; 11: 275-286.
25. Lund LH, Edwards LB, Kucheryavaya AY et al. The registry of the International Society for Heart and Lung Transplantation: Thirtieth official adult heart transplant report-2013; focus theme: Age. J Heart Lung Transplan 2013; 32: 951-964.
26. MirotsouM, JayawardenaTM, Schmeckpeper J et al. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. JMol Cell Cardiol 2011; 50: 280-289.
27. Heldman AW, DiFede DL, Fishman JE et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: The TAC-HFT randomized trial. JAMA 2014; 311: 62-73.
28. Henry TD, Traverse JH, Hammon BL et al. Safety and efficacy of ixmyelocel-T: An expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. Circ Res 2014; 115: 730-737.
29. Vrtovec B, Poglajen G, Lezaic L et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation 2013; 128(suppl 1): S42-S49.